Halozyme (HALO) Q3 2026 earnings review
Halozyme's newer drug royalties double, and European courts block Merck
Halozyme, whose enzyme technology lets doctors inject intravenous drugs under the skin, is getting a bigger boost from newly launched partner medicines while its older blockbusters keep growing. Royalty revenue jumped 44% to $341 million and total sales climbed 39% to $493 million, right in line with what the prior plan pointed to. Finance chief Darren Snellgrove raised the full-year outlook again, though by our math the new target leaves fourth-quarter revenue growth slowing to 20% against a tough milestone comparison.
| Royalty revenue | $341.0M +44.5% from a year ago |
|---|---|
| Total revenue | $493.0M +39.2% from a year ago |
| Profit per share, excluding one-offs | $2.39 +39.0% from a year ago |
| Full-year royalty outlook | Raised $12.5M middle of the range: 43.5% growth |
⚖️ Verdict: 🟢 Bullish
The story got better because four newer partner drugs nearly doubled their royalties and three more candidates entered human trials, cutting reliance on Halozyme's top three medicines. Chief executive Dr. Helen Torley also won a Dutch court ban blocking Merck's competing Keytruda shot across eight European countries. One caution: Halozyme lost initial patent rulings against Merck in the United States, and its unrevised 2027 targets now sit only 12% above this year's raised royalty plan by our math.
The question now is whether royalty growth stays high in 2027 or drops toward the low double-digit pace implied by the standing multi-year targets. Either management has simply waited until year-end to lift those multi-year numbers, or older cancer drugs are nearing saturation before the next wave of clinical programs launches in 2029. The formal 2027 outlook on the February call will settle it.
🐂 Bull Case
New Drug Launches Reduce Royalty Concentration
Halozyme licenses ENHANZE, an enzyme that lets doctors inject intravenous drugs under the skin in minutes. For years, three established medicines generated over four-fifths of its royalties, creating concentration risk. Now, a newer group of four partner drugs is growing fast enough to broaden the base.
- Newer drug royalties: up 92% from a year ago to $65.1 million, reaching 19.1% of total royalties by our math
- Vyvgart Hytrulo (an autoimmune therapy by argenx): royalties jumped 89% to $88.1 million
- Darzalex (Johnson & Johnson's blood cancer therapy) and Phesgo (Roche's breast cancer therapy): royalties rose 20% to $153.5 million and 23% to $34.3 million
- Ocrevus Zunovo (Roche's multiple sclerosis drug): reached 56,000 patients, adding 12,000 since midyear and crossing 20% conversion
This matters because the newer medicines are bringing in fresh patients, not just switching existing ones. Chief executive Dr. Helen Torley noted that half of patients starting Ocrevus Zunovo are new to the brand, and Bristol Myers Squibb already converted 17% of its intravenous Opdivo cancer business to the under-the-skin version.
What to watch: the royalty share outside the top three drugs in the fourth quarter. If that share crosses one-fifth of total royalties, the newer cohort can offset slower growth as older cancer drugs mature.
Three Clinical Starts Put the Pipeline Goal in Reach
Drugmakers pay Halozyme upfront fees to test its delivery enzyme with their antibodies, then pay royalties if the drugs win approval four to five years later. Halozyme set a target of having 13 partner programs in human trials by the end of 2026, up from nine in June.
During the third quarter, Pfizer, Incyte and argenx each moved an ENHANZE drug into Phase 1 human testing, bringing the active clinical count to 12. Existing partners argenx, Incyte and Johnson & Johnson also expanded their agreements to add four new drug targets, while GSK plans to start a Phase 1b trial for its multiple myeloma drug belantamab by year-end.
What to watch: confirmation in February that GSK started its trial and brought the pipeline to 13 clinical programs. Reaching that mark keeps up to 13 new drug launches on schedule between 2029 and 2032.
Dutch Court Blocks Merck in Eight European Countries
Halozyme is suing Merck over Keytruda Qlex, an under-the-skin version of the blockbuster cancer drug that uses a rival enzyme from Alteogen. Halozyme claims Merck infringes its MDASE patents, which cover a broader family of modified delivery enzymes.
In October, a Dutch patent court rejected Merck's invalidity arguments and "granted an injunction prohibiting the launch of Keytruda Qlex in multiple European markets", Torley said. Along with an earlier German ban, the orders block Merck across nine European countries that typically generate about 20% of global under-the-skin royalties, and Halozyme also sued Merck's Italian contract manufacturer BSP Pharmaceuticals.
What to watch: any licensing settlement with Merck or supply disruption from the Italian factory lawsuit in 2027. A European licensing agreement would create a new royalty stream without clinical risk.
🐻 Bear Case
Higher 2026 Targets Leave Little Growth in the 2027 Plan
Chief executive Dr. Helen Torley said Halozyme's expanding pipeline "positions us to deliver durable revenue well into the next decade." Finance chief Darren Snellgrove raised the 2026 outlook again, lifting the middle of the royalty range by $12.5 million to $1.245 billion, or 43.5% growth by our math.
Yet management did not update its multi-year targets for 2027 and 2028, which it issued early this year. Snellgrove said only that "we remain very comfortable with the outlook and look forward to providing the update" in February. By our math, the standing 2027 target of $1.365 billion to $1.415 billion in royalties now sits just 11.6% above the raised 2026 plan, and total revenue sits only 4.8% higher.
That gap cuts against the durability pitch because core ENHANZE patents begin expiring in 2029, and Darzalex royalties end in the early 2030s. Torley noted that seven of ten launched drugs hold joint formulation patents, while newer agreements carry a royalty rate cut if patents expire. Either the 2027 targets are outdated, or growth slows sharply next year.
What to watch: the formal 2027 royalty outlook on the fourth-quarter call in February. A target near the old $1.39 billion middle of the range would confirm that royalty growth drops from 43% to just over 10%.
US Patent Losses and Acquisition Risks Persist
Outside Europe, Halozyme faces legal and balance-sheet hurdles from its push to build new revenue streams before 2029. Last late year, the company spent $1.1 billion to buy two drug-concentration startups, Elektrofi (maker of Hypercon) and Surf Bio (now called Aerocon), neither of which has a drug in human trials yet.
- US Merck litigation: Halozyme "received adverse validity decisions on multiple of our PGRs" at the US patent board, with appeals lasting until 2028
- Hypercon target review: when asked about a partner evaluating whether to return a licensed drug target, Torley said "we really can't say any more about that"
- Debt load: issued $1.5 billion in new convertible notes, pushing total debt to $3.25 billion and net debt to 2.4 times cash profit
This matters because losing a Hypercon partner target could force an accounting writedown of the $893 million in intangible assets on the balance sheet. Meanwhile, Keytruda Qlex continues selling freely in the United States while appeals drag on.
What to watch: the first two Hypercon Phase 1 clinical trial starts in the first half of 2027 and the partner target decision by February. Any further delay or returned target would test the value of the $1.1 billion acquisition spend.
👓 Other Themes
Enzyme Shipments and Acquisition Costs Trimmed Operating Margin
Operating margin fell 1.7 percentage points from a year ago to 59.8%. Halozyme noted that "The increase in cost of sales was primarily due to an increase in bulk rHuPH20 sales" to partners, which lifted production costs by 1.1 points of revenue to 16.7%. Intangible amortization and research costs from the Elektrofi and Surf Bio acquisitions added 1.0 point and 0.8 points of revenue, outweighing a 1.2-point drop in overhead.
💲 Other KPIs
Net product sales jumped 45.7% from a year ago as Halozyme shipped more bulk enzyme to drug partners and grew its own injector products. At the same time, inventories on the balance sheet fell 24.9% since December to $132.6 million. Management raised its full-year product sales plan to $525 million to $540 million.
Fees from signing and milestone agreements dropped 39.0% from a year ago and fell from $43.7 million last quarter. These payments depend on when partners sign deals or start clinical trials. Management kept its full-year collaborative revenue target at $110 million to $130 million, which by our math leaves about $56 million for the fourth quarter.
Uncollected billings and contract assets owed by drug partners rose 19.1% from $441.3 million at the end of 2025. Because Halozyme records royalties in the same quarter its partners sell the drugs, receivables naturally climb alongside quarterly royalty revenue, which has expanded by a third since the fourth quarter of last year.
The share count used to calculate profit per share excluding one-offs fell 1.2% from 120.3 million a year ago. Halozyme spent $67.2 million in the third quarter to buy back about 0.8 million shares at an average price of $79.47, finishing its $400 million buyback plan for 2026 while excluding 3.7 million shares tied to convertible debt.
🔮 Guidance
Raised. The middle of the range moved up $20 million to $1.893 billion, or 35.5% growth over 2025 by our math. That leaves about $542 million for the fourth quarter, which points to 19.9% growth against a tough prior-year comparison that included $71.1 million in deal milestones. It is the second raise this year after moves of $0 million, +$112.5 million, and +$20 million.
Raised. Snellgrove said "Royalties remain the engine of our business and the main driver of this raise", lifting the middle of the range by $12.5 million to 43.5% growth. By our math, the full-year target leaves $355.6 million for the fourth quarter, or 37.9% growth from a year ago, down from 44.5% in the third quarter. Prior moves this year were $0 million, +$82.5 million, and +$12.5 million.
Raised. Cash operating profit excluding one-offs moved up $12.5 million at the middle of the range to $1.265 billion, or 92.4% growth over 2025, which had a large acquisition write-off. The plan still includes about $60 million of spending on Hypercon and Aerocon. By our math, the outlook implies a 68.4% margin in the fourth quarter, matching the 68.2% posted in the third quarter.
Raised. The middle of the profit-per-share target rose by $0.075 to $8.90, representing 114.5% growth over 2025 by our math. Through the first nine months, Halozyme has earned $6.27 per share on this basis, leaving $2.63 for the fourth quarter. The company noted that the range includes the $60 million research investment and does not assume any further share buybacks in the fourth quarter.
❓ Key Questions
Why has a partner not decided on the Hypercon target?
For two quarters, filings have noted a partner evaluating whether to return a licensed Hypercon drug target, and Torley declined to comment on the call. A returned target without a replacement could trigger a writedown of the $893 million intangible asset balance.
How much royalty growth will the 2027 update add?
After two raises to 2026 targets, the unrevised 2027 royalty forecast of $1.365 billion to $1.415 billion implies growth slowing from 43.5% this year to 11.6% next year. Investors need to know in February whether 2027 moves up alongside the higher 2026 base.
Does the Italian lawsuit threaten Merck's US Keytruda Qlex supply?
The Dutch injunction blocks Merck's European entity from using BSP Pharmaceuticals in Italy to make Keytruda Qlex, and Halozyme sued BSP directly. Because BSP is the FDA-approved filler for the US product, the suit could test whether European rulings disrupt US supply.
Will Halozyme settle the 2027 and 2028 notes in cash?
Snellgrove cited "maintaining a clear path to retire our remaining 2027 and 2028 notes at maturity" after raising $1.5 billion in new convertible debt. Clarifying whether conversion premiums will be paid entirely in cash determines how much dilution hits GAAP share counts.